WCM Investment Management LLC Invests $8.72 Million in TransMedics Group, Inc. (NASDAQ:TMDX)

WCM Investment Management LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 54,795 shares of the company's stock, valued at approximately $8,720,000. WCM Investment Management LLC owned about 0.16% of TransMedics Group at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. International Assets Investment Management LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas purchased a new position in TransMedics Group in the 3rd quarter valued at approximately $55,000. J.Safra Asset Management Corp grew its holdings in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock worth $67,000 after acquiring an additional 383 shares in the last quarter. Signaturefd LLC raised its position in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company's stock worth $67,000 after acquiring an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after acquiring an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Needham & Company LLC dropped their price objective on TransMedics Group from $208.00 to $109.00 and set a "buy" rating on the stock in a report on Tuesday, October 29th. Baird R W raised TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. Oppenheimer cut their target price on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 29th. JPMorgan Chase & Co. reduced their price target on shares of TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 29th. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of "Buy" and an average target price of $144.80.

TransMedics Group Stock Up 2.6 %

NASDAQ:TMDX traded up $2.30 during trading hours on Tuesday, reaching $91.41. The company's stock had a trading volume of 1,665,842 shares, compared to its average volume of 957,488. The stock has a 50 day moving average price of $130.45 and a two-hundred day moving average price of $139.89. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 12 month low of $56.83 and a 12 month high of $177.37. The company has a market capitalization of $3.07 billion, a P/E ratio of 101.04 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group's revenue was up 63.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.12) EPS. Equities analysts predict that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Nicholas Corcoran sold 10,000 shares of the firm's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company's stock, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company's stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock worth $5,230,528 in the last three months. Corporate insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.